Research overview based on the cited scientific literature.

• Goal: Support metabolic homeostasis, enhance insulin sensitivity, and promote healthy aging through AMPK activation[1][2].

• Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); use within 2–4 weeks[11][12].

Proper storage helps preserve research material integrity[11][12].

• Lyophilized material: Keep sealed, dry, protected from light and moisture, and under appropriate frozen-storage conditions for longer-term laboratory preservation[11][12].

• Prepared solutions: Refrigerated stability depends on formulation, solvent, concentration, handling conditions, and product-specific stability data. Follow the applicable laboratory or supplier documentation rather than assuming a universal storage period[9][12].

• Handling: Allow cold-stored vials to equilibrate appropriately before opening to reduce condensation, and avoid unnecessary repeated freeze–thaw cycles[11][12].

• Use appropriate aseptic laboratory handling practices and minimize unnecessary exposure to light, heat, and moisture.

MOTS-C is a mitochondrial‑derived peptide that activates AMPK‑driven metabolic pathways to enhance glucose uptake, increase fat oxidation, and reduce lipid accumulation in muscle and adipose tissue[1][2]. Preclinical studies demonstrate that daily MOTS-C administration (5 mg/kg i.p. in mice) prevents diet‑induced obesity and insulin resistance[2], while short 7‑day courses restore insulin sensitivity in aged mice to youthful levels. Unlike metformin (which acts primarily in the liver), MOTS-C directly targets skeletal muscle and fat tissues[2]. The peptide also translocates to the nucleus under metabolic stress to regulate nuclear gene expression[4]. Endogenous MOTS-C levels rise sharply with exercise (~12‑fold increase in muscle)[3] and decline with age, suggesting therapeutic potential for age‑related metabolic decline. No formal human clinical trials have been completed to date; current human use is investigational and based on preclinical findings[6].

Observations from preclinical and emerging investigational use.

Potential Benefits

• Enhanced insulin sensitivity and glucose metabolism in muscle and fat tissue[1][2].
• Increased fat oxidation and reduced diet‑induced obesity in animal models[2].
• Improved exercise capacity and muscle homeostasis during aging[3].
• Modest lifespan extension in rodents with intermittent dosing (15 mg/kg 3×/week)[2].
• No stimulation of IGF‑1 or adverse effects on glucose tolerance (contrast with growth hormone).
• Well‑tolerated in animal studies with no severe adverse effects at typical doses.

Potential Side Effects

• Mild injection‑site reactions (temporary redness, inflammation, or bruising) reported anecdotally.
• No severe adverse effects or organ toxicity observed in preclinical studies at standard doses[6].
• Long‑term human safety data not yet available; chronic continuous use beyond 8 weeks remains uncharacterized.
• Theoretical risk of downregulation with prolonged daily use; cycling approach (4–8 weeks on, equal time off) recommended.

The cited MOTS-c literature is dominated by preclinical, mechanistic, and observational research, and current evidence does not establish clinical efficacy or long-term safety for therapeutic use in humans[1][5].

Additional controlled human research is needed to define pharmacology, safety, clinically relevant outcomes, and longer-term effects. Findings from cellular and animal studies should not be assumed to translate directly to human clinical benefit[1].